Close this search box.

A randomised trial of Conventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases

CORE is a phase II/III, multicentre, non-blinded, randomised controlled trial in patients with breast, prostate or non-small cell lung cancer (NSCLC) primary cancer to evaluate if the addition of stereotactic body radiotherapy (SBRT) to standard therapy improves progression-free survival outcomes in patients with extra-cranial metastases that have spread from either their lung, breast and/or prostate cancer.

Primary Sponsor

The Institute of Cancer Research (UK)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Final Accrual


Closing Date of Accrual

February 2019

Trial Chairperson

A/Prof David Pryor, Princess Alexandra Hospital, QLD
A/Prof Farshad Foroudi, Austin Health - Olivia Newton John Cancer and Wellness Centre, VIC

Trial Contact

Related Post

October 18, 2022

NINJA Radiation Therapy Trial participant tells his journey to treatment

The journey to becoming the 200th participant for the

September 6, 2022

The gift that kept on giving

The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing